Dept. of Physiology and Biophysics, Univ. of Mississippi Medical Center, 2500 North State St., Jackson, MS 39216-4505, USA.
Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15;302(2):R259-63. doi: 10.1152/ajpregu.00319.2011. Epub 2011 Nov 9.
While soluble fms-like tyrosine kinase-1 (sFlt-1) and endothelin-1 (ET-1) have been implicated in the pathogenesis of preeclampsia (PE), the mechanisms whereby increased sFlt-1 leads to enhanced ET-1 production and hypertension remain unclear. It is well documented that nitric oxide (NO) production is reduced in PE; however, whether a reduction in NO synthesis plays a role in increasing ET-1 and blood pressure in response to chronic increases in plasma sFlt-1 remains unclear. The purpose of this study was to determine the role of reduced NO synthesis in the increase in blood pressure and ET-1 in response to sFlt-1 in pregnant rats. sFlt-1 was infused into normal pregnant (NP) Sprague-Dawley rats (3.7 μg·kg(-1)·day(-1) for 6 days beginning on day 13 of gestation) treated with the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester (100 mg/l for 4 days) or supplemented with 2% L-Arg (in drinking water for 6 days beginning on day 15 of gestation). Infusion of sFlt-1 into NP rats significantly elevated mean arterial pressure compared with control NP rats: 116 ± 2 vs. 103 ± 1 mmHg (P < 0.05). NO synthase inhibition had no effect on the blood pressure response in sFlt-1 hypertensive pregnant rats (121 ± 3 vs. 116 ± 2 mmHg), while it significantly increased mean arterial pressure in NP rats (128 ± 4 mmHg, P < 0.05). In addition, NO production was reduced ∼70% in isolated glomeruli from sFlt-1 hypertensive pregnant rats compared with NP rats (P < 0.05). Furthermore, prepro-ET-1 in the renal cortex was increased ∼3.5-fold in sFlt-1 hypertensive pregnant rats compared with NP rats. Supplementation with L-Arg decreased the sFlt-1 hypertension (109 ± 3 mmHg, P < 0.05) but had no effect on the blood pressure response in NP rats (109 ± 3 mmHg) and abolished the enhanced sFlt-1-induced renal cortical prepro-ET expression. In conclusion, a reduction in NO synthesis may play an important role in the enhanced ET-1 production in response to sFlt-1 hypertension in pregnant rats.
可溶性 fms 样酪氨酸激酶-1(sFlt-1)和内皮素-1(ET-1)已被认为与子痫前期(PE)的发病机制有关,但是导致 sFlt-1 增加的机制如何导致 ET-1 产生和高血压尚不清楚。有充分的证据表明,一氧化氮(NO)的产生在 PE 中减少;然而,NO 合成的减少是否在慢性增加血浆 sFlt-1 引起的 ET-1 和血压增加中起作用仍不清楚。本研究的目的是确定在怀孕大鼠中,NO 合成减少在 sFlt-1 引起的血压和 ET-1 增加中的作用。sFlt-1 被输注到正常妊娠(NP)Sprague-Dawley 大鼠中(从妊娠第 13 天开始,每天 3.7μg·kg(-1),连续 6 天),并用一氧化氮合酶抑制剂 N(G)-硝基-L-精氨酸甲酯(100mg/l,连续 4 天)处理,或用 2% L-Arg(从妊娠第 15 天开始,连续 6 天,在饮用水中补充)处理。与对照 NP 大鼠相比,sFlt-1 输注到 NP 大鼠中显著升高平均动脉压:116 ± 2 对 103 ± 1mmHg(P < 0.05)。NO 合酶抑制对 sFlt-1 高血压妊娠大鼠的血压反应没有影响(121 ± 3 对 116 ± 2mmHg),而在 NP 大鼠中则显著增加了平均动脉压(128 ± 4mmHg,P < 0.05)。此外,与 NP 大鼠相比,sFlt-1 高血压妊娠大鼠的分离肾小球中的 NO 产生减少了约 70%(P < 0.05)。此外,在 sFlt-1 高血压妊娠大鼠的肾皮质中,前 ET-1 增加了约 3.5 倍。L-Arg 的补充降低了 sFlt-1 高血压(109 ± 3mmHg,P < 0.05),但对 NP 大鼠的血压反应没有影响(109 ± 3mmHg),并消除了增强的 sFlt-1 诱导的肾皮质前 ET 表达。总之,NO 合成的减少可能在怀孕大鼠中 sFlt-1 高血压引起的 ET-1 产生增加中起重要作用。